Ultragenyx Pharmaceutical Stock Discussion

» Holdings: 87
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte(INCY.US)$
$BeiGene(BGNE.US)$
$ACADIA Pharmaceuticals(ACAD.US)$
$Madrigal Pharmaceuticals(MDGL.US)$
$Rhythm Pharmaceuticals(RYTM.US)$
$Revolution Medicines(RVMD.US)$
$Kymera Therapeutics(KYMR.US)$
$AbCellera Biologics(ABCL.US)$
$Bicycle Therapeutics(BCYC.US)$
$Edgewise Therapeutics(EWTX.US)$
$Immunocore(IMCR.US)$
$Kodiak Sciences(KOD.US)$
$Roivant Sciences(ROIV.US)$
...

$United Therapeutics(UTHR.US)$  Phase 3
$Ironwood Pharmaceuticals(IRWD.US)$  Phase 3
$Liquidia(LQDA.US)$  Phase 3
$United Therapeutics(UTHR.US)$  Phase 3
$MorphoSys(MOR.US)$  Phase 3
$Immunocore(IMCR.US)$  Phase 3
$Crinetics(CRNX.US)$  Phase 3
$UroGen Pharma Ltd(URGN.US)$  Phase 3
$AstraZeneca(AZN.US)$  Phase 3
$AstraZeneca(AZN.US)$  Phase 3
$AstraZeneca(AZN.US)$  Phase 3
$AstraZeneca(AZN.US)$  Phase 3
$Capricor Therapeutics(CAPR.US)$  Phase 3
$Annexon(ANNX.US)$  Phase 3
$Lipocine(LPCN.US)$  Phase 3...

$Travere Therapeutic(TVTX.US)$  Phase 3
$CG Oncology(CGON.US)$  Phase 3
$United Therapeutics(UTHR.US)$  Phase 3
$United Therapeutics(UTHR.US)$  Phase 3
$BioCardia(BCDA.US)$  Phase 3
$Insmed(INSM.US)$  Phase 3
$GlycoMimetics(GLYC.US)$  Phase 3
$Annexon(ANNX.US)$  Phase 3
$Lipocine(LPCN.US)$  Phase 3
$FibroGen(FGEN.US)$  Phase 3
$UroGen Pharma Ltd(URGN.US)$  Phase 3
$Lyra Therapeutics(LYRA.US)$  Phase 3
$Citius Pharmaceuticals(CTXR.US)$  Phase 3
$Jaguar Health(JAGX.US)$  Phas...

🎯 Ph 3 readouts in Q2 2024...
$Intra-Cellular Therapies(ITCI.US)$  Phase 3
$CG Oncology(CGON.US)$  Phase 3
$Hutchmed (China)(HCM.US)$  Phase 3
$Viracta Therapeutics(VIRX.US)$  Phase 3
$GlycoMimetics(GLYC.US)$  Phase 3
$Annexon(ANNX.US)$  Phase 3
$Lipocine(LPCN.US)$  Phase 3
$FibroGen(FGEN.US)$  Phase 3
$UroGen Pharma Ltd(URGN.US)$  Phase 3
$Lyra Therapeutics(LYRA.US)$  Phase 3
$Citius Pharmaceuticals(CTXR.US)$  Phase 3
$Marinus Pharmaceuticals(MRNS.US)$  Phase 3
$BioCardia(BCDA.US)$  Phase 3...

Gainers:
In reaction to earnings/guidance:
• $Silvergate Capital(SI.US)$ +10.7% (Silvergate (ticker: SI) notched net income of $38.6 million in the June quarter, delivering earnings per share (EPS) of $1.13.)
• $AxoGen(AXGN.US)$ +3.3% (guides Q2 revs above consensus; also makes changes to its commercial organization),
• $Novartis AG(NVS.US)$ + 3% (The Swiss pharmaceutical company on Tuesday posted net profit of $1.69 billion, down from...

Upgrades
• $ACADIA Pharmaceuticals(ACAD.US)$: Canaccord Genuity Upgrades to Buy from Hold - PT $31 (from $30)
• $Host Hotels & Resorts(HST.US)$: Raymond James Upgrades to Outperform from Market Perform - PT $21
• $Magna International(MGA.US)$: Raymond James Upgrades to Market Perform from Underperform - PT $68
• $Micron Technology(MU.US)$: Bernstein Upgrades to Outperform from Market Perform - PT $94 (from $58)
• $Ultragenyx Pharmaceutical(RARE.US)$: Credit Sui...